/Zylö Therapeutics

Portfolio Company | Life Sciences 

Zylö Therapeutics has developed a sustained-release drug delivery system. The delivery system uses patented xerogel-derived particles, called Z-pods™, to sustainably deliver Nitric Oxide and other notoriously hard-to-deliver therapeutic agents through topical administration. The technology enables a product concept called the Patchless Patch™, an innovative, competitive response to a lidocaine patch. The company recently announced a signed term sheet with Hoth Therapeutics to co-develop a new treatment — using endocannabinoid-loaded Z-pods™ — for patients suffering from Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin. The Series A funding will be used to scale the manufacturing process of the company’s Z-pod™ particles and to forge additional development and commercial partnerships. Visit Company Website

By | 2020-05-05T20:57:56+00:00 August 21st, 2018|0 Comments